Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25923241 | 0.92 | NPC1 (0.45) | NPC1RAB9ATSHRHRH3TP53 | |
| SCHEMBL23945808 | 0.81 | SIGMAR1 (0.46) | NPC1RAB9AHRH3TP53ALDH1A1 | |
| SCHEMBL26317521 | 0.79 | SIGMAR1 (0.56) | NPC1RAB9AHRH3TP53ALDH1A1 | |
| SCHEMBL24765472 | 0.77 | NPC1 (0.42) | NPC1RAB9ATSHRHRH3TP53 | |
| SCHEMBL23945982 | 0.76 | RAB9A (0.44) | NPC1RAB9ATSHRHRH3TP53 | |
| SCHEMBL22790807 | 0.76 | ALDH1A1 (0.65) | NPC1RAB9ATSHRHRH3TP53 | |
| SCHEMBL21587353 | 0.73 | LMNA (0.62) | NPC1RAB9AHRH3TP53ALDH1A1 | |
| SCHEMBL21587322 | 0.72 | HRH3 (0.65) | TSHRHRH3ALDH1A1MEN1KMT2A | |
| SCHEMBL25829623 | 0.72 | NCF1 (0.58) | NPC1RAB9ATSHRTP53ALDH1A1 | |
| SCHEMBL25701636 | 0.71 | NPC1 (0.41) | NPC1RAB9ATSHRHRH3TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885RAB9A 4270/4885TSHR 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.